In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 0.05 below Citius Pharmaceuticals Inc average.

Within Major Pharmaceutical Preparations industry 432 other companies have achieved higher Quick Ratio than Citius Pharmaceuticals Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 3736 to 4043.

Explain Quick Ratio?
How much Cash & cash equivalents CTXR�s has?
What are CTXR�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/CTXR/financial-strength

https://api.csimarket.com/api/v1/companies/CTXR/fundamentals

https://api.csimarket.com/api/v1/companies/CTXR/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

CTXR Quick Ratio	(Jun 30 2026) Q3	(Mar 31 2026) Q2	(Dec 31 2025) Q1	(Sep 30 2025) Q4	(Jun 30 2025) Q3
Y / Y Current Liabilities Change	1602.3 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	179.31 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	0.05	Subscribe	Subscribe	Subscribe	Subscribe
CTXR's Total Ranking	# 4043	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	507.01 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	270.52 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 433
Healthcare Sector	# 873
Overall Market	# 4043

Quick Ratio Statistics
High	Average	Low
34.76	3.85	0
(Mar 31 2021)		(Mar 31 2013)

Financial Statements
Citius Pharmaceuticals Inc 's Current Liabilities	$ 334 Millions	Visit CTXR's Balance sheet
Citius Pharmaceuticals Inc 's Cash & cash equivalent	$ 17 Millions	Visit CTXR's Balance sheet
Source of CTXR's Sales		Visit CTXR's Sales by Geography

Cumulative Citius Pharmaceuticals Inc 's Quick Ratio

CTXR's Quick Ratio for the trailling 12 Months

CTXR Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	20.36 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	103.09 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	0.07	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 4106	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	199.25 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	48.2 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to CTXR Financial Strength Comparisons >> Go to Compare CTXR Quick Ratio to its Competitors

On the trailing twelve months basis Due to in Current Liabilities in the Q3 2026 to $333.95 millions, cumulative Quick Ratio decreased to 0.07 a new company low.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 443 other companies have achieved higher Quick Ratio than Citius Pharmaceuticals Inc . While Quick Ratio overall ranking has improved so far to 4106, from total ranking during the twelve months ending second quarter 2026 at 4111.

Explain Quick Ratio?
How much Cash & cash equivalents CTXR�s has?
What are CTXR�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 444
Healthcare Sector	# 910
Within the Market	# 4106

trailing twelve months Quick Ratio Statistics
High	Average	Low
24.71	3.6	0
(Dec 31 2021)		(Dec 31 2013)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Cumberland Pharmaceuticals Inc	0.11	$ 3.862 Millions	$ 35.193 Millions
Igc Pharma Inc	0.11	$ 0.354 Millions	$ 3.287 Millions
Tuhura Biosciences Inc	0.11	$ 0.996 Millions	$ 9.255 Millions
Gridai Technologies Corp	0.10	$ 1.380 Millions	$ 14.146 Millions
Bioxcel Therapeutics Inc	0.09	$ 12.841 Millions	$ 137.149 Millions
Lunai Bioworks Inc	0.09	$ 1.714 Millions	$ 18.910 Millions
Galectin Therapeutics Inc	0.09	$ 13.275 Millions	$ 151.619 Millions
Lftd Partners Inc	0.08	$ 0.304 Millions	$ 3.648 Millions
Processa Pharmaceuticals Inc	0.08	$ 0.196 Millions	$ 2.387 Millions
Vogenx, Inc.	0.06	$ 0.193 Millions	$ 3.188 Millions
Cv Sciences Inc	0.05	$ 0.266 Millions	$ 4.943 Millions
Citius Pharmaceuticals Inc	0.05	$ 17.008 Millions	$ 333.952 Millions
Sunshine Biopharma Inc	0.05	$ 0.281 Millions	$ 5.619 Millions
Hcw Biologics Inc	0.04	$ 0.741 Millions	$ 18.648 Millions
China Pharma Holdings Inc	0.04	$ 0.305 Millions	$ 7.682 Millions
Bioxytran Inc	0.03	$ 0.177 Millions	$ 5.275 Millions
Cdt Equity Inc	0.03	$ 0.700 Millions	$ 23.351 Millions
Shuttle Pharmaceuticals Holdings Inc	0.03	$ 0.102 Millions	$ 3.481 Millions
Northwest Biotherapeutics Inc	0.01	$ 0.595 Millions	$ 42.982 Millions
Oncotelic Therapeutics Inc	0.01	$ 0.186 Millions	$ 17.907 Millions

Date modified: 2026-11-04T14:32:41+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.